Top Markets
#1 Siren Siren +34.29%
#2 Wiki Cat Wiki Cat +30.30%
#3 Bitway Bitway +20.25%
#4 Ribbita by Virtuals Ribbita by Virtuals +19.79%
#5 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +17.45%
#6 PulseChain PulseChain +16.92%
#7 TRIA TRIA +16.78%
#8 Velvet Velvet +15.27%
#9 Cysic Cysic +14.22%
#10 The Grays Currency The Grays Currency +14.20%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc

FRLN
Rank in Stocks #30823
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in... Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.
Share Price
$6.48
Last synced: 2024-02-29
Market Cap
$15.41M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade Freeline Therapeutics Holdings plc (FRLN)

Category

Healthcare
P/E ratio for Freeline Therapeutics Holdings plc (FRLN)
P/E ratio as of 2026 TTM: 0
According to Freeline Therapeutics Holdings plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Freeline Therapeutics Holdings plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.